Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.36 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717170 | 0.98 | PIP4K2A (0.35) | PIP4K2APIP4K2BPIP4K2CATRATRIP | |
| SCHEMBL470164 | 0.92 | HTR6 (0.37) | PIP4K2APIP4K2BPIP4K2CATRATRIP | |
| SCHEMBL715407 | 0.82 | PIP4K2A (0.38) | PIP4K2APIP4K2BPIP4K2CATRATRIP | |
| SCHEMBL713193 | 0.79 | SLC9A1 (0.36) | SLC9A1NR1H2NR1H3HTR6 | |
| SCHEMBL714369 | 0.76 | PIK3CG (0.46) | ATRATRIPPIK3CDPIK3CBABL1 | |
| SCHEMBL459027 | 0.74 | HTR6 (0.41) | PIP4K2APIP4K2BPIP4K2CATRATRIP | |
| SCHEMBL463569 | 0.74 | HTR6 (0.39) | PIP4K2APIP4K2BPIP4K2CATRATRIP | |
| SCHEMBL720486 | 0.74 | PIK3CA (0.41) | PIK3CDPIK3CBPIK3CGPIK3CAMTOR | |
| SCHEMBL461128 | 0.73 | BRD4 (0.31) | PIK3CD | |
| SCHEMBL716071 | 0.72 | ATR (0.35) | PIP4K2APIP4K2BPIP4K2CATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIP4K2A 1280/4885PIP4K2B 1186/4885PIP4K2C 1455/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | PIP4K2A 12/4885PIP4K2B 8/4885PIP4K2C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.